Prognosis
Pandemic, Democratic Wins Leave Drug Industry at Crossroads
- Pricing reform again on table in new U.S. political reality
- Health companies, analysts meet at annual Morgan conference
This article is for subscribers only.
In 2020, the pharmaceutical industry raced to develop shots against a deadly new virus sweeping the globe -- and succeeded, in record time. They did it while navigating the pandemic themselves, managing operations and supply chains amid profound disruption.
As the J.P. Morgan Healthcare Conference, the sector’s biggest annual gathering, kicks off virtually on Monday, drugmakers are set to revel in those accomplishments. But their enthusiasm is bound to be muffled by the prospect of increased regulation and price pressure.